Galapagos Investor Seeks to Influence Company Control, Citing Undervaluation

Investor Influence:
An investor in Galapagos NV has signaled an intent to influence the company's control, arguing that the biotech firm is "deeply undervalued".

Ownership Structure:
Individual investors own a significant portion of Galapagos, with the top 13 shareholders holding 50% of the company. Institutions own 19%, and public companies, including Gilead Sciences, Inc., hold 25%.

Insider Ownership:
Insiders own less than 1% of Galapagos, indicating a low level of internal control.

Recent Developments:
Galapagos has reported half-year 2024 financial results and provided a second-quarter business update, highlighting its focus on developing transformational medicines in oncology and immunology.

Conservation Efforts:
Separate from the company's operations, a significant debt-for-climate conversion was announced in 2023 to protect the Galapagos Islands, involving a $1.628 billion exchange for a $656 million impact loan.